Skip to content
Review

Safety and early outcomes of external beam radiation therapy with low dose brachytherapy boost in patients with prostate cancer: A single institution experience.

Oct 2026 · Brachytherapy · 0 citations · 26 references
Medicine

TL;DR

Findings support this approach for appropriately selected patients in routine clinical care for intermediate- and high-risk prostate cancer, as contemporary real-world evidence remains limited.

Abstract

Purpose

To evaluate the safety and early oncologic outcomes of external beam radiation therapy (EBRT) combined with a low-dose-rate (LDR) brachytherapy boost in patients with intermediate- and high-risk prostate cancer, as contemporary real-world evidence remains limited.

Methods

AND MATERIALS Investigators retrospectively reviewed 307 patients treated at a large tertiary cancer center between 1999 and 2024. Median age was 66 years; 36% had intermediate-risk and 64% had high- or very high-risk disease, and 91% received androgen deprivation therapy. Late gastrointestinal (GI) and genitourinary (GU) toxicities were defined as occurring more than three months after radiation initiation and graded using CTCAE version 5. Biochemical failure was defined using Phoenix criteria. Outcomes were summarized descriptively; Cox regression analyzed overall survival (OS) and biochemical recurrence-free survival (bRFS), while Fine-Gray models evaluated late toxicity with death as a competing risk.

Results

At a median follow-up of 4.6 years, 22 patients developed biochemical recurrence. Five-year bRFS was 98% for intermediate-risk disease and 90% for high- or very high-risk disease; OS and bRFS were 92% and 95%, respectively. Grade 3 or higher GU and GI toxicity occurred in 3.2%, and no significant predictors of severe late toxicity were identified.

Conclusion

These findings support this approach for appropriately selected patients in routine clinical care.

View source

Similar papers

Sep 2026

High-dose-rate brachytherapy boost with external beam radiotherapy for localized prostate cancer: Long-term outcomes and toxicity in 607 predominantly high-risk patients.

OBJECTIVE To report long-term outcomes and late toxicity after external beam radiotherapy (EBRT) with single-fraction high-dose-rate brachytherapy boost (HDR-BTB) for localized prostate cancer, examining HDR-BT sequencing and risk stratification. METHODS AND MATERIALS We retrospectively analyzed 607 (2012-2023) men t...

M. Choudhury, F. Adeoye, S. Nageshwaran et al. · 0 citations
Open access Sep 2026

Long-term outcome after partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy: Results from a Phase II prospective study with extended follow-up.

PBI using interstitial multi-catheter high dose-rate brachytherapy is effective and well-tolerated for selected early-stage breast cancer showing excellent long-term toxicity, cosmetic profiles, and outcomes.

Valeria Epifani, P. Anselmo, F. Arcidiacono et al. · 0 citations
Oct 2026

Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial.

DE-fsHDR is a safe and effective salvage treatment for IPR and GC score is a promising prognostic tool in patients undergoing salvage local therapy for IPR and warrants further study to guide treatment intensification.

A. Solanki, William Adams, James A. Proudfoot et al. · 0 citations
Open access Sep 2026

Image-guided high-dose-rate brachytherapy after short-course external beam radiotherapy for elderly/frail rectal cancer patients.

HDR-BT dose escalation after initial EBRT represents a feasible non-operative treatment option for patients unfit for surgery with promising long-term local control and the incidence of late grade 3 rectal bleeding requires careful patient selection.

Alexander Kristen, N. Tselis, M. Diefenhardt et al. · 0 citations
Open access Sep 2026

Long-term outcomes of high-dose hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer.

High-dose hyperfractionated radiotherapy may be a feasible dose-escalated option for patients with LS-SCLC, with acceptable toxicity, with published data on the long-term outcomes of this specific regimen.

Yasuhito Hagiwara, Yuuki Kuroda, Kenji Takai et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.